MRSN

Stats

Summary

mersana is rewriting the rules for immunoconjugate therapies by leveraging our fleximer platform to create precisely targeted and highly tailored drugs that radically improve patients’ lives. our fleximer platform allows us to custom design an adc with specific properties to overcome limitations of current adc approaches and increase the drug’s chances of effectively attacking a particular cancer. we engineer immunoconjugates to deliver industry-leading payloads of an array of anti-tumor agents directly to cancerous cells, controlling when, where and how those agents are released. because we can safely deliver higher quantities of therapeutic payloads directly to a tumor, mersana’s adc therapies have the potential to more effectively treat broader populations of cancer patients while significantly reducing the side effects associated with many of today’s cancer treatments.

Market Cap: 696 Million

Primary Exchange: NASDAQ

Website: http://www.mersana.com/

Shares Outstanding: 121 Million

Float: 0

Dividend: 0.0 (0.0%)

Beta: 1.4106159190911072

Sector: Manufacturing

Industry: Pharmaceutical Preparation Manufacturing

Ethical Flags

Longest drawdown: 1032 trading days

From: 2020-12-23 To: 2024-03-07

Lowest Point:

Ex-Date	Payment Date	Record Date	Declared Date	Amount	Flag	Dividend Type	Qualified	Indicated

Ex-Date	Declared Date	Record Date	Payment Date	Ratio	To Factor	For Factor